OXIDATIVE STRESS INTENSITY AND STATE OF SEPARATE ANTIOXIDANT PROTECTION FACTORS IN ANTRALE TREATMENT IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS, OBESITY, AND CHRONIC OBSTRUCTIVE LUNG DISEASE
Article PDF (Українська)

Keywords

non-alcoholic steatohepatitis, obesity, chronic obstructive pulmonary disease, oxidative stress, antral

How to Cite

O. S. Khukhlina, O. Ye. Hryniuk, & A. A. Antoniv. (2020). OXIDATIVE STRESS INTENSITY AND STATE OF SEPARATE ANTIOXIDANT PROTECTION FACTORS IN ANTRALE TREATMENT IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS, OBESITY, AND CHRONIC OBSTRUCTIVE LUNG DISEASE. Eastern Ukrainian Medical Journal, 8(2), 129-136. https://doi.org/10.21272/eumj.2020;8(2):129-136

Abstract

The aim of the research was to assess the effectiveness of Antral regarding to the impact on the intensity of lipid peroxidation, antioxidant system factors in NASH patients against the background of obesity and comorbidity with COPD.

Material and methods of research: 76 NASH patients with class I obesity of and COPD 2-3 D were examined: 23 patients (group 1 – control group) received basic NASH therapy (Esentsiale forte N (Sanofi Avensis/Nutterman and Cie GmbH) 300 mg, 2 caps., 3 times per day) for 30 days and COPD therapy (Symbicort Turbuhaler (budesonide 160 mg/d + formoterol fumarate 4,5 mg/s) (AstraZeneca AB, Sweden) inhaled 2 times per day for 30 days, Berodual (ipratropium/fenoterol (250/500 mg/ml) (Institute de Angele Italy/Boehringer Ingelheim International GmbH) nebulizer inhalation 2 times per day, azithromycin (Azithro Sandoz, Ukraine Sandoz) 500 mg, 1 time per day for 10 days). The second group (basic group, B1) consisted of 25 NASH patients with class I obesity and COPD 2-3 D, in addition to the same basic COPD therapy, they received Antral (Farmak, Ukraine) 200 mg, 3 times per day for 60 days as a hepatoprotector. The third group (basic group, B2) included 28 NASH patients with class I obesity and COPD 2-3 D, except the same basic COPD treatment, they received Antral (Farmak, Ukraine) 200 mg, 3 times per day as a hepatoprotector, and Phytostatin (Polyconazole) (OmniFarma LLC, Ukraine) 20 mg after dinner for 30 days.

Research results. In NASH patients against the background of obesity and COPD, a significant intensity of oxidative stress has been established with an increase in the blood of intermediate and final products of lipid peroxidation content (in 1.7–2.2 times, p < 0.05) against the background of a significant deficit in the restored glutathione in the blood (in 1.6 times, p < 0.05), which was accompanied by a compensatory voltage of catalase activity (increases in 1.7 times, p < 0.05).

Conclusion. The combined prescription of Antral for 30 days led to a significant correction of oxidative-antioxidant homeostasis in NASH patients against the background of obesity and COPD with a probable decrease of malonic aldehyde, isolated double bonds, conjugated dienes (p < 0.05), a probable increase the reduced glutathione content in red blood cells (p < 0.05).

 

https://doi.org/10.21272/eumj.2020;8(2):129-136
Article PDF (Українська)

References

1. Khukhlina OS, Antoniv AA, Mandryk OIe, Hryniuk OIe. Nealkoholna zhyrova khvoroba pechinky ta komorbidni stany: osoblyvosti patohenezu, kliniky, diahnostyky, likuvannia: kol. monoh. [Non-alcoholic fatty liver disease and comorbid conditions: especially pathogenesis, clinical features, diagnosis, treatment]. Chernivtsi. 2018:58-61. ISBN 978-966-697-546-4. (in Ukrainian).
2. Anokhina AA. Nealkoholna zhyrova khvoroba pechinky yak multysystemne metabolitne zakhvoriuvannia: osoblyvosti profilaktyky ta likuvannia [Non-alcoholic fatty liver disease as a multisystem metabolic disease: features of prevention and treatment]. Hepatolohiia. 2018;7(3):35-40. (in Ukrainian).
3. Fadieienko HD, Kushnir IE, Chernova VM, et al. Nutryhenetychna kharakterystyka khvorykh z nealkoholnoiu zhyrovoiu khvoroboiu pechinky na tli metabolichnoho syndrome [Nutrigenetic characteristic of patients with non-alcoholic fatty liver disease against the background of metabolic syndrome]. Suchasna hastroenterolohiia. 2018;6 (104):7-13. (in Ukrainian).
4. Italian Association for the Study of the Liver. AISF position paper on nonalcoholic fatty liver disease (NAFLD): updates and future directions. Dig Liver Dis 2017; 49: 471–483. doi.org/10.3390/ijms20081948
5. Anstee QM, Targher G, Day CP Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat. Rev. Gastroenterol. Hepatol. 2013. 10: 330–344. doi: 10.1038/nrgastro.2013.41.
6. Chalasani N, Younossi Z, Lavine JE et al. The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Am. J. Gastroenterol. 2012. 107 (6): 811–826. doi: 10.1002/hep.25762.
7. Chacko KR, Reinus J. Extrahepatic complications of nonalcoholic fatty liver disease. Clin Liver Dis. 2016;20(2):387-401. doi: 10.1016/j.cld.2015.10.004.
8. Baltieri L, Chaim EA, Chaim FDM, et al. Correlation between nonalcoholic fatty liver disease features and levels of adipokines and inflammatory cytokines among morbidly obese individuals. Arq Gastroenterol. 2018;55(3):247-251. doi: 10.1590/S0004-2803.201800000-62.
9. Viglino D, Jullian-Desayes I, Minoves M, et al.: Nonalcoholic fatty liver disease in chronic obstructive pulmonary disease. Eur Respir J. 2017; 49(6): pii: 1601923. doi: 10.1183/13993003.01923-2016.
10. Jung DH, Shim JY, Lee HR, et al. Relationship between non-alcoholic fatty liver disease and pulmonary function. Intern Med J 2012; 42: 541–546. doi: 10.1111/j.1445-5994.2011.02644.x.
11. Babak OJa, Fadeenko GD, Kolesnikova EV. Opyt primenenija preparata antral' v sostave kompleksnoj terapii nealkogol'noj zhirovoj bolezni pecheni [The experience of using the drug Antral as part of the complex treatment of non-alcoholic fatty liver disease]. Zdorov’ja Ukraїni. Temat. nomer: Gastroenterologіja. Gepatologіja. Koloproktologіja. 2010; 1:26–27. (in Russian).
12. Zvjaginceva TD. Primenenie preparata Antral' v lechenii nealkogol'nogo steatogepatita: nastojashhee i budushhee [The use of the drug Antral in the treatment of non-alcoholic steatohepatitis: present and future]. Medichna gazeta «Zdorov’ja Ukraїni XXI storіchchja». 2015;1(2):68–69. (in Russian).
13. Kuzminov BP, Matysik SI, Zazuliak TS, Mykytchak TI. Otsinka hostroi toksychnosti hepatoprotektora antraliu na alternatyvnykh test-systemakh [Evaluation of acute toxicity of hepatoprotector antral on alternative test systems]. Environment & health. 2016; 2: 43-46. (in Ukrainian).
14. Sukhpreet Singh, Natalia A Osna, Kusum K Kharbanda. Treatment options for alcoholic and non-alcoholic fatty liver disease: A review. World journal of gastroenterology. 2018; 23(36): 6549-6570. doi: 10.3748/wjg.v23.i36.6549
15. Serhienko OO, Serhienko VO, Hotsko ME. ta in. Porivnialnyi analiz efektyvnosti polikozanolu ta symvastatynu v korektsii porushen lipidnoho obminu, parametriv insulinovoi rezystentnosti u khvorykh na tsukrovyi diabet 2-ho typu z dyslipidemiieiu [Comparative analysis of the effectiveness of polycosanol and simvastatin in the correction of lipid metabolism disorders, insulin resistance parameters in patients with type 2 diabetes mellitus with dyslipidemia.]. Klinichna endokrynolohiia ta endokrynna khirurhiia. 2013; 2 (43):21—29. (in Ukrainian).
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.